EP2204177B1 - Cancer marker and therapeutic agent for cancer - Google Patents
Cancer marker and therapeutic agent for cancer Download PDFInfo
- Publication number
- EP2204177B1 EP2204177B1 EP09177321.8A EP09177321A EP2204177B1 EP 2204177 B1 EP2204177 B1 EP 2204177B1 EP 09177321 A EP09177321 A EP 09177321A EP 2204177 B1 EP2204177 B1 EP 2204177B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cancer
- bmcc1
- expression
- seq
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Not-in-force
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 113
- 201000011510 cancer Diseases 0.000 title claims description 107
- 239000003814 drug Substances 0.000 title claims description 29
- 229940124597 therapeutic agent Drugs 0.000 title claims description 28
- 239000000439 tumor marker Substances 0.000 title description 8
- 230000014509 gene expression Effects 0.000 claims description 142
- 101000736906 Homo sapiens Protein prune homolog 2 Proteins 0.000 claims description 132
- 102100036040 Protein prune homolog 2 Human genes 0.000 claims description 102
- 108020004459 Small interfering RNA Proteins 0.000 claims description 71
- 206010060862 Prostate cancer Diseases 0.000 claims description 53
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 43
- 210000001519 tissue Anatomy 0.000 claims description 31
- 108091034117 Oligonucleotide Proteins 0.000 claims description 26
- 229960004316 cisplatin Drugs 0.000 claims description 22
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 22
- 239000002246 antineoplastic agent Substances 0.000 claims description 12
- 206010005003 Bladder cancer Diseases 0.000 claims description 9
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 9
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 9
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 9
- 206010046766 uterine cancer Diseases 0.000 claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 7
- 206010017758 gastric cancer Diseases 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- 201000011549 stomach cancer Diseases 0.000 claims description 7
- 239000000051 antiandrogen Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 96
- 241000282414 Homo sapiens Species 0.000 description 45
- 239000003098 androgen Substances 0.000 description 42
- 108090000623 proteins and genes Proteins 0.000 description 41
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 26
- 108020004414 DNA Proteins 0.000 description 26
- 230000001629 suppression Effects 0.000 description 21
- 238000003757 reverse transcription PCR Methods 0.000 description 17
- 230000035899 viability Effects 0.000 description 17
- 239000000523 sample Substances 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 15
- 101150015801 PRUNE2 gene Proteins 0.000 description 14
- 108020004999 messenger RNA Proteins 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 230000001419 dependent effect Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 230000003833 cell viability Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 101000862137 Trichoderma koningii Glyceraldehyde-3-phosphate dehydrogenase 1 Proteins 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 238000010804 cDNA synthesis Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000010195 expression analysis Methods 0.000 description 5
- 238000012744 immunostaining Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000004055 small Interfering RNA Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 206010029260 Neuroblastoma Diseases 0.000 description 4
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 4
- 108091027967 Small hairpin RNA Proteins 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000009368 gene silencing by RNA Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- ZKTPOUXCUHYLDZ-SAYNGHPTSA-N C(CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12)(=O)NCCCCNC(=O)C1CCC(CC1)CN1C(C=CC1=O)=O Chemical compound C(CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12)(=O)NCCCCNC(=O)C1CCC(CC1)CN1C(C=CC1=O)=O ZKTPOUXCUHYLDZ-SAYNGHPTSA-N 0.000 description 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 108020004417 Untranslated RNA Proteins 0.000 description 3
- 102000039634 Untranslated RNA Human genes 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 108091027963 non-coding RNA Proteins 0.000 description 3
- 102000042567 non-coding RNA Human genes 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 102000003952 Caspase 3 Human genes 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 2
- -1 acetal diethylaminoacetate Chemical class 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 101150028074 2 gene Proteins 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- DHMYGZIEILLVNR-UHFFFAOYSA-N 5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione;1h-pyrimidine-2,4-dione Chemical compound O=C1C=CNC(=O)N1.O=C1NC(=O)C(F)=CN1C1OCCC1 DHMYGZIEILLVNR-UHFFFAOYSA-N 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010087905 Adenovirus E1B Proteins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100037135 BCL2/adenovirus E1B 19 kDa protein-interacting protein 2 Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101710162682 Glyceraldehyde-3-phosphate dehydrogenase 1 Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000740576 Homo sapiens BCL2/adenovirus E1B 19 kDa protein-interacting protein 2 Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101001106406 Homo sapiens Rho GTPase-activating protein 1 Proteins 0.000 description 1
- 241000243328 Hydridae Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 1
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102100021433 Rho GTPase-activating protein 1 Human genes 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000012288 TUNEL assay Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000009454 functional inhibition Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000021419 recognition of apoptotic cell Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003463 sulfur Chemical class 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229940061532 tegafur / uracil Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57442—Specifically defined cancers of the uterus and endometrial
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
- G01N2333/4707—Guanosine triphosphatase activating protein, GAP
Definitions
- the present invention relates to a cancer marker and a therapeutic agent for cancer.
- Prostate cancer is the cancer which has the highest prevalence among males in Europe and the U.S. Also in Japan, the number of patients with prostate cancer is increasing year by year along with westernization of dietary habits and aging of the population.
- Prostate cancer includes an androgen-dependent tumor and an androgen-independent tumor.
- proliferation of prostate cancer cells is stimulated by androgen; therefore, in treatment of unresectable progressive prostate cancer, androgen blockade therapy, which inhibits production and function of androgen, is frequently implemented.
- Early-stage prostate cancer often responds to androgen blockade therapy because most of it is androgen dependent. However, once it has progressed to an androgen-independent tumor, androgen blockade therapy cannot be implemented, and even more, no good treatment method exists. In view of the foregoing, effective treatment for androgen-independent tumor is needed.
- a BMCC1 gene is a novel gene discovered as a result of a research project "a comprehensive gene expression analysis in tumor tissue using a cDNA microarray derived from a tumor of neuroblastoma and identification of a cancer suppressor gene, an oncogene, and a prognosis-determining factor using the same" in Chiba Cancer Center, by which a strong correlation between BMCC1 gene expression and prognosis of neuroblastoma was reported (Patent Document 1 and Non-Patent Document 1). However, involvement of the BMCC1 gene in prostate cancer is not known.
- Patent Document 1 Japanese Patent Laid-Open No. 2003-061672
- Non-Patent Document 1 Machida, T. et al., (2006), Oncogene, Vol. 25, p1931-1942
- an object of the present invention is to provide a novel cancer marker.
- Another object of the present invention is to provide a novel therapeutic agent for cancer.
- the present inventors found that the BMCC1 gene was expressed in tissues other than neural tissue in which expression of the gene had been previously known, and BMCC1 gene expression in prostate cancer, lung cancer, gastric cancer, bladder cancer, and uterine cancer was reduced compared with a normal specimen based on experimental results of an expression analysis of cancer tissue.
- the present inventors further found that BMCC1 gene expression was enhanced when DD3 expression was suppressed by DD3-specific siRNA. Combined with the findings that DD3 expression is enhanced in early-stage prostate cancer, while BMCC1 expression is suppressed in late-stage prostate cancer, the aforementioned findings suggest a possibility that DD3 inhibits BMCC1 gene expression and promotes cancer progression.
- the present inventors completed the present invention based on the findings as described above.
- the present invention provides a method for detecting cancer using a level of BMCC1 gene expression in a specimen as an indication, in which the cancer is selected from the group consisting of bladder cancer, and uterine cancer.
- the method for detecting cancer is characterized by including a step of measuring a level of BMCC1 gene expression in a specimen with a suspicion of cancer, a step of comparing the level of BMCC1 gene expression with levels of BMCC1 gene expression in a normal specimen and in a cancer specimen, and a step of judging the specimen suspect of being affected by cancer as cancer in a case where the level of BMCC1 gene expression in the specimen with a suspicion of cancer is (i) lower than the level of BMCC1 gene expression in the normal specimen, (ii) the same level as the level of BMCC1 gene expression in the cancer specimen, or falls into both (i) and (ii).
- the specimen is preferably a cell or a piece of tissue.
- the method for detecting cancer according to the present invention is based on findings discovered by the inventors of the present application that the BMCC1 gene is expressed in tissues other than neural tissue in which expression of the gene has been previously known, and BMCC1 gene expression in prostate cancer, lung cancer, gastric cancer, bladder cancer, and uterine cancer is reduced compared with a normal tissue. Provision of a cancer marker for a method for detecting cancer is made possible by the above findings.
- the present invention provides siRNA which targets DD3, in which the siRNA is double-stranded siRNA comprising a pair of oligonucleotides of any one of (a) to (d) as described below;
- the present disclosure further provides a therapeutic agent for cancer containing the siRNA described above as an active ingredient.
- the cancer described above is preferably selected from the group consisting of prostate cancer, lung cancer, gastric cancer, bladder cancer, and uterine cancer, among which it is more preferably prostate cancer.
- DD3 is a non-coding RNA which is known as a prostate cancer marker.
- DD3 is encoded by q21.13 of chromosome 9, and interestingly, it is inserted in reverse orientation in intron 6 of the BMCC1 gene ( FIG. 1 ), based on which the inventors of the present application established a hypothesis that DD3 suppressively regulates BMCC1 gene expression.
- the hypothesis was examined in Examples of the present application.
- the inventors of the present application found for the first time that BMCC1 gene expression was enhanced and viability of cancer cells is more effectively suppressed by suppression of DD3 expression by DD3-specific siRNA.
- the present invention is based on the above-described findings, and delay in cancer progression and improvements in symptoms of cancer can be expected by a therapeutic agent of the present invention.
- the present invention provides a therapeutic agent for cancer, which further contains an anti-cancer agent.
- the anti-cancer agent is preferably cisplatin.
- the present invention provides a therapeutic agent for cancer, which further contains an anti-androgen agent.
- the cancer is preferably prostate cancer.
- the present invention is based on a finding that viability of cancer cells is more effectively suppressed when treatment with cisplatin and/or removal of androgen are/is employed concurrently in addition to inhibition of DD3 expression, and delay in cancer progression, improvements in symptoms of cancer, and the like can be expected by the therapeutic agent of the present invention.
- the BMCC1 gene which stands for B CH motif- c ontaining molecule at the c arboxyl terminal region 1 , is a gene identified by the inventors of the present application as a gene involved in determination of prognosis of neuroblastoma in Japanese Patent Laid-Open No. 2003-061672 and Machida, T. et al., (2006), Oncogene, Vol. 25, p1931-1942 .
- GenBank Accession No. of the gene is AB050197.
- BMCC1 protein is 340 kDa in size, and has Bc12/Adenovirus E1B 19 kDa interacting protein 2 (i.e., BNIP2) and Cdc42GAP homology domain (i.e., BCH domain) in a C terminal side thereof.
- FIG. 1 schematically shows chromosomal locations of human BMCC1 gene, PRUNE2 gene, and DD3 gene. As shown in FIG. 1 , the BMCC1 gene locates in q21.13 of human chromosome 9. Also, in the same chromosomal region, a PRUNE 2 gene is present (GenBank Accession No. NM138818).
- DD3 gene was inserted in reverse orientation in intron 6 of the BMCC1 gene. Namely, a sequence of the DD3 gene was perfectly complementary to a part of intron 6 of the BMCC1 gene.
- DD3 encoded by the DD3 gene (GenBank Accession No. AF103907) is a non-coding RNA (i.e., ncRNA), which is also called a prostate cancer antigen (i.e., PCA). It is known as a prostate cancer marker; however, involvement of DD3 in a mechanism of tumorigenesis has not been elucidated.
- BMCC1 gene expression is enhanced by specifically suppressing DD3 expression, an effect is expected from the standpoint of cancer treatment and delay in cancer progression. Furthermore, as shown in Examples 7 and 8 below, it has been found that viability of cancer cells can be more effectively suppressed when treatment with cisplatin and/or removal of androgen are/is employed concurrently in addition to suppression of DD3 expression. Accordingly, it was suggested that combination use of the therapeutic agent of the present invention and another treatment method which employs an anti-cancer agent, an anti-androgen agent, and the like was effective.
- a method for detecting cancer according to the present embodiment is described.
- the method for detecting cancer according to the present embodiment is based on a level of BMCC1 gene expression as an indication.
- the method detects a cancer cell or cancer tissue based on the finding of the present invention that there is a correlation between a low level of BMCC1 gene expression and cancer.
- the method for detecting cancer includes a step of measuring a level of BMCC1 gene expression in a specimen with a suspicion of cancer, a step of comparing the level of BMCC1 gene expression with levels of BMCC1 gene expression in a normal specimen and in a cancer specimen, and a step of judging the specimen suspect of being affected by cancer as cancer in a case where the level of BMCC 1 gene expression in the specimen with a suspicion of cancer is (i) lower than BMCC1 gene expression in the normal specimen, (ii) the same level as the level of BMCC1 gene expression in the cancer specimen, or falls into both (i) and (ii).
- a preferred subject can be a human.
- the cancer is preferably selected from the group consisting of prostate cancer, lung cancer, gastric cancer, bladder cancer, and uterine cancer, among which it is more preferably prostate cancer.
- the specimen is preferably a cell or a piece of tissue which is susceptible to onset of cancer to be examined.
- a level of gene expression refers to a level of mRNA expression, which is a transcription product of the gene, and/or a level of protein expression, which is a translation product of the mRNA.
- a level of mRNA expression can be measured by a measurement system publicly known to a person skilled in the art, and specific examples thereof include a semi-quantitative RT-PCR method, a quantitative real-time RT-PCR method, a quantitative Northern blotting method, and a quantitative ribonuclease protection method.
- a level of protein expression can be measured by a measurement system publicly known to a person skilled in the art, and examples thereof include a quantitative Western blotting method and an ELISA method.
- levels of mRNA and/or protein expression of GAPDH which is a housekeeping gene, beta-actin, and the like as a control
- the level of expression of an objective gene such as a BMCC1 gene
- levels of objective gene expression and/or control gene expression in an aliquot derived from a plurality of samples and/or an identical sample obtained from an identical subject are measured, and the level of expression can be obtained from a mean value of each of them.
- Gene expression can be quantitatively measured by using these methods.
- Primers and probes for detecting BMCC1 mRNA can be designed by a method commonly known to a person skilled in the art.
- primers for detecting BMCC1 mRNA a BMCC1 (BNF2/BNR2) primer set (SEQ ID NOS: 1 and 2), a kiaa0367F/R primer set (SEQ ID NOS: 8 and 9), and the like are exemplified; however, the primers are not limited to these examples.
- an antibody, an antibody fragment, and the like for detecting BMCC 1 protein can be prepared by a method commonly known to a person skilled in the art.
- an antibody raised against an epitope containing residues from 2074 to 2093 of BMCC1 protein i.e., amino acid sequence: AKKPFSLKADGENPDILTHC, as shown by single-letter codes of amino acids; SEQ ID NO: 23
- an antibody raised against an epitope containing residues from 3068 to 3088 of BMCC1 protein i.e., amino acid sequence: YNDPEMSSMEKDIDLKLKEKP (as shown by single-letter codes of amino acids; SEQ ID NO: 36)
- an antibody raised against an epitope containing residues from 1733 to 1753 of BMCC1 protein i.e., amino acid sequence: KSENIYDYLDSSEPAENENKSNPFC (as shown by single-letter codes of amino acids; SEQ ID NO: 37)
- a commercially available antibody, and the like are preferably used; however, the antibody is not limited to these examples.
- the level of BMCC1 gene expression in a normal specimen can be obtained by statistically processing a measurement value of a level of expression which is obtained from a specimen derived from a plurality of normal tissue which are not oncogenically transformed obtained from single or a plurality of subject(s) (a control group). Also, the level of BMCC1 gene expression in a cancer specimen can be obtained by statistically processing measurement values of a level of expression obtained from specimens derived from a plurality of cancer tissues obtained from single or a plurality of patient(s) of cancer (a disease group).
- a specimen with a suspicion of cancer is judged as a cancer specimen in a case where the level of BMCC1 gene expression in the specimen with a suspicion of cancer is lower than the level of BMCC1 gene expression in the normal specimen, and/or in a case where, in comparison with the level of expression obtained from the control group, the level of BMCC1 gene expression statistically corresponds to a range lower than a distribution range of the control group.
- a specimen with a suspicion of cancer is judged as a cancer specimen in a case where the level of BMCC1 gene expression in the specimen with a suspicion of cancer is the same level as the level of BMCC1 gene expression in the cancer specimen, and/or in a case where, in comparison with the level of expression obtained from the disease group, the level of BMCC1 gene expression statistically corresponds to a distribution range of the disease group. Furthermore, a specimen with a suspicion of cancer is judged as a cancer specimen in a case where the level of BMCC1 gene expression in the specimen with a suspicion of cancer falls into both (i) and (ii).
- siRNA which targets DD3 is double-stranded siRNA comprising a pair of oligonucleotides of any one of (a) to (d) as described below;
- siRNA is an abbreviation for short interfering RNA, and refers to a double-stranded RNA having 10 or more base pairs which is obtained by artificial chemical synthesis or biochemical synthesis, or by synthesis inside a body of an organism, or by degradation of double-stranded RNA having approximately 40 or more bases inside a body.
- a length of siRNA is generally 10-30-base long, preferably approximately 15-25-base long, more preferably around 19-23-base long.
- the siRNA usually has a structure of 5'-phosphate and 3'-OH, and approximately 2 bases overhang at the 3'-end thereof.
- RNA interference RNA interference
- protein specific to the siRNA binds thereto to form a RISC (i.e., RNA-induced-silencing-complex).
- the complex recognizes and binds to mRNA having a sequence identical to the siRNA, and cleaves the mRNA at a center of the siRNA by an RNase III-like enzymatic activity.
- siRNA can inhibit expression of a target gene (i.e., DD3 gene in the present invention) by degrading mRNA having a sequence homologous to the siRNA.
- a phenomenon described above is called RNA interference (RNAi).
- the RNAi phenomenon is a phenomenon observed in nematodes, insects, protozoa, hydras, plants, and vertebrates (including mammals).
- siRNA specific to DD3 other than the ones described above can be used.
- shRNA i.e., short hairpin RNA
- dsRNA i.e., double strand RNA
- siRNA is produced inside the cell.
- a promoter of an RNA polymerase III (Pol III) which participates in a transcription system of U6RNA or H1RNA can be used as a promoter for the expression vector of the RNA.
- the siRNA described above can be RNA, RNA : DNA hybrid, or a modified nucleic acid (RNA and DNA).
- modified nucleic acid(s) can be sulfur derivatives and thiophosphate derivatives of nucleic acid(s), as well as ones resistant to degradation of polynucleotide amide and oligonucleotide amide; however, the modified nucleic acid(s) are not limited to these examples.
- the therapeutic agent for cancer according to the present embodiment has the siRNA described above as an active ingredient.
- the therapeutic agent for cancer can contain the siRNA singly or 2 or more thereof in combination.
- a pharmaceutically acceptable carrier can be added as needed in accordance with a conventional method.
- it can be a surfactant, an excipient, a colorant, a scent, a preservative, a stabilizer, a buffer, a suspending agent, a tonicity agent, a binder, a disintegrant, a lubricant, a fluidity promoter, and a flavor; however, it is not limited to these examples, and a carrier which is ordinarily used can be employed as appropriate.
- Specific examples thereof can be light anhydrous silicic acid, lactose, crystalline cellulose, mannitol, starch, carmellose calcium, carmellose sodium, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, polyvinyl acetal diethylaminoacetate, polyvinylpyrrolidone, gelatin, medium-chain fatty acid triglyceride, polyoxyethylene hardened castor oil 60, sucrose, carboxymethylcellulose, corn starch, an inorganic salt, and the like.
- kinds of formulation of the therapeutic agent for cancer according to the present invention can be, for example, an oral agent such as a tablet, a pulverized agent, a pill, a powder, a granule, a fine granule, soft and hard capsules, a film-coated preparation, a pellet, a sublingual agent, and a paste, as well as a parenteral agent such as an injection, a suppository, a percutaneous agent, an ointment, a plaster, and a liquid preparation for external use, and a person skilled in the art can select a most suitable dosage form according to an administration route, a subject to be administered, and the like.
- a prepared product can contain 0.1 to 99.9% by weight of the siRNA described above as an active ingredient.
- a daily dose is generally, for example, approximately 0.1 mg to 1,000 mg, preferably approximately 1.0 to 100 mg, more preferably approximately 1.0 to 50 mg for a patient (supposed to weigh 60 kg) in a case of oral administration.
- a dose per administration differs depending on a subject to be administered, a target organ, a symptom, a method of administration, and the like, for example, it is convenient in a case of an injection, generally, for example, to administer at approximately 0.01 to around 30 mg, preferably at approximately 0.1 to around 20 mg, more preferably at approximately 0.1 to around 10 mg daily to a patient (supposed to weigh 60 kg) by an intravenous injection.
- the dose can ultimately be determined as appropriate based on judgment of a physician in consideration of a kind of dosage form, an administration method, age and weight of a patient, a patient's symptoms, and the like.
- the therapeutic agent for cancer according to the present invention is used for prevention and treatment of prostate cancer, lung cancer, gastric cancer, bladder cancer, uterine cancer, and the like, and it is preferably used for prevention and treatment of prostate cancer.
- the therapeutic agent for cancer according to the present invention can be used in combination with an anti-cancer agent.
- the anti-cancer agent can be cisplatin, peplomycin, ifosfamide, tegafur/uracil, estramustine, docetaxel, gemcitabine, oxaliplatin, and the like, among which it is preferably cisplatin.
- the therapeutic agent for cancer according to the present invention can be used in combination with an anti-androgen agent.
- the therapeutic agent for cancer according to the present invention can be used in combination with an anti-cancer agent and an anti-androgen agent.
- Example 1 An expression analysis of BMCC1 gene, PRUNE2 gene, and DD3 gene in human normal tissue
- RNA extracted from human normal tissue product of Clontech Laboratories, Inc.
- a semiquantitative RT-PCR was conducted following the below-described experimental procedures to examine mRNA expression of BMCC1 gene, PRUNE2 gene, and DD3 gene.
- cDNA was synthesized following a protocol of the product.
- 2 ⁇ g of the total RNA and random primers Random Hexamers, product of Invitrogen Corporation
- a PCR reaction was carried out with the following conditions.
- a tube containing a reaction solution of the above composition was set in a thermal cycler (Gene Amp@ PCR System 9700, product of Applied Biosystems).
- a thermal cycler Gene Amp@ PCR System 9700, product of Applied Biosystems.
- a BMCC1 (BNF2/BNR2) primer set SEQ ID NOS: 1 and 2
- a sample was heated to 95°C for 2 minutes, after which a cycle containing 95°C for 15 seconds ⁇ 59°C for 15 seconds ⁇ 72°C for 20 seconds was repeated 38 times, and the sample was kept at 72°C for 6 minutes.
- a sample was heated to 95°C for 2 minutes, after which a cycle containing 95°C for 15 seconds ⁇ 59°C for 15 seconds ⁇ 72°C for 20 seconds was repeated 38 times, and the sample was kept at 72°C for 7 minutes.
- a DD3 (F3/R3) primer set SEQ ID NOS: 4 and 5
- a sample was heated to 95°C for 2 minutes, after which a cycle containing 95°C for 15 seconds ⁇ 63°C for 15 seconds ⁇ 72°C for 20 seconds was repeated 38 times, and the sample was kept at 72°C for 6 minutes.
- a sample was heated to 95°C for 2 minutes, after which a cycle containing 95°C for 15 seconds ⁇ 58°C for 15 seconds ⁇ 72°C for 20 seconds was repeated 28 times, and the sample was kept at 72°C for 6 minutes.
- the PCR products thus obtained were subjected to electrophoresis on 2% agarose gel and detected by ethidium bromide (product of SIGMA Corporation).
- BMCC1 gene, PRUNE2 gene, and DD3 gene expression in human normal tissue as examined by a semiquantitative RT-PCR are shown in FIG. 2 .
- BMCC1 expression was confirmed in tissues other than the neural system in which BMCC1 expression had been reported.
- DD3 was expressed prominently in the prostate gland.
- Example 2 An expression analysis of BMCC1 gene and DD3 gene in a matched pair of human normal tissue and cancer tissue
- BMCC1 expression in various cancer was examined using a matched pair of normal tissue and cancer tissue derived from patients of lung cancer (2 patients), gastric cancer (2 patients), bladder cancer (4 patients), uterine cancer (1 patient), and prostate cancer (2 patients) by an RT-PCR method.
- Example 1 The method described in Example 1 was employed except that a total RNA extracted from a matched pair of human normal tissue and cancer tissue (product of Clontech Laboratories, Inc.) was used and a kiaa0367F/R primer set (SEQ ID NOS: 8 and 9) was used in addition to a BNF2/BNR2 primer set (SEQ ID NOS: 1 and 2) as a primer for detecting BMCC1.
- a PCR reaction using a BMCC1 (kiaa0367F/R) primer set was carried out by heating the sample to 95°C for 2 minutes and repeating a cycle containing 95°C for 15 seconds ⁇ 61°C for 15 seconds ⁇ 72°C for 20 seconds 35 times, followed by keeping the sample at 72°C for 6 minutes.
- BMCC1 gene and DD3 gene were expressed in the matched pair of human normal tissue and cancer tissue as examined by a semiquantitative RT-PCR.
- BMCC1 expression was found to be reduced in a cancer site compared with a normal site, which suggested that a functional inhibition of BMCC1 in cancer was caused by reduction in its expression.
- DD3 expression was enhanced in a plurality of cancer tissues.
- Example 3 An expression analysis of BMCC1 gene, PRUNE2 gene, and DD3 gene in a prostate cancer cell line
- DD3 suppressively regulates BMCC1 gene expression
- expression of BMCC1 gene, PRUNE2 gene, and DD3 gene was confirmed in a cell line established from prostate cancer according to the following method.
- LNCaP cell line An LNCaP cell line, a PC3 cell line, and a Du145 cell line, all of which were cell lines established from prostate cancer, were provided by Dr. Ueda (Director of Department of Urology, Chiba Cancer Center) and used in this examination.
- the LNCaP cell is an androgen dependent cell line, while the PC3 cell and the Du145 cell are androgen independent cell lines. Properties of these cell lines are shown in Table 1. Also, a SK-N-BE cell line, which was a neuroblastoma cell line, was used as a control.
- Example 1 Cultured cells of each cell line (80% confluent in a 100 mm dish) were collected and suspended in 1 mL of ISOGEN (product of Nippon Gene Co., Ltd.), from which a total RNA was purified following a protocol of the product.
- ISOGEN product of Nippon Gene Co., Ltd.
- the methods described in Example 1 were employed for cDNA synthesis and PCR reactions except that a F3/R primer set (SEQ ID NOS: 4 and 10) was used in addition to a F3/R3 primer set (SEQ ID NOS: 4 and 5) as a primer for detecting DD3.
- a PCR reaction using a DD3 (F3/R) primer set was carried out by heating the sample to 96°C for 5 minutes and repeating a cycle containing 96°C for 30 seconds ⁇ 62°C for 60 seconds 35 times.
- BMCC1 gene, PRUNE2 gene, and DD3 gene in a prostate cancer cell line as examined by a semiquantitative RT-PCR are shown in FIG. 4 .
- DD3 was confirmed to be highly expressed in androgen dependent LNCaP cells.
- BMCC1 was highly expressed in LNCaP cells as well, while BMCC1 expression was reduced in PC3 cells and Du145 cells, which may correspond to prostate cancer with higher malignancy.
- a semiquantitative RT-PCR was carried out using a total RNA extracted from prostate cancer cell lines (an LNCaP cell line and a PC3 cell line) into which siRNA was introduced.
- siRNA 1, 2, and 3 Three kinds of siRNA for DD3 were designed and purchased from Integrated DNA Technologies, Inc. A structure of DD3 ncRNA and locations of siRNA for DD3 are shown schematically in FIG. 5 . Sequences of the three kinds of siRNA to DD3 (i.e., DD3 siRNA 1, 2, and 3) are as follows;
- HiPerfect a product of QIAGEN, was used for transduction of siRNA.
- Cultured cells of each cell line were transduced with 5 nM of each siRNA according to a protocol of the product. The cultured cells were collected 48 hours after transduction and a total RNA was purified according to a protocol of the product.
- the methods described in Examples 1 to 4 were used for cDNA synthesis and PCR reactions except that, as a primer for detecting DD3, a DD3 (F3/R) primer set (SEQ ID NOS: 4 and 10) was used in FIG. 6 , and a DD3 (taqF4/taqR2) primer set (SEQ ID NOS: 21 and 22) was used in FIG. 7 .
- a BMCC1 (BNF2/BNR2) primer set (SEQ ID NOS: 1 and 2) was used, and as a primer for detecting PRUNE2, a PRUNE2 (BNF2/PRUNE2R1) primer set (SEQ ID NOS: 1 and 3) was used, and as a primer for detecting GAPDH1, a GAPDH1 (F/R) primer set (SEQ ID NOS: 6 and 7) was used.
- a tube containing a reaction solution of the above composition containing LA-Taq (product of Takara Bio Inc.) was set in a thermal cycler (Gene Amp@ PCR System 9700, product of Applied Biosystems) and heated to 95°C for 2 minutes. After that, a cycle containing 95°C for 15 seconds ⁇ 60°C for 15 seconds ⁇ 72°C for 20 seconds was repeated 35 times, and the sample was kept at 72°C for 7 minutes.
- FIGS. 6 and 7 The results of expression of BMCC1 gene, PRUNE2 gene, and DD3 gene in a prostate cancer cell line into which siRNA for DD3 was introduced as examined by a semiquantitative RT-PCR are shown in FIGS. 6 and 7 . As a result, any of the siRNA was confirmed to inhibit DD3 expression ( FIGS. 6 and 7 ). It was elucidated that in cells in which DD3 expression was inhibited, BMCC1 expression was enhanced in both of the LNCaP cells and the PC3 cells regardless of androgen dependency ( FIG. 6 ).
- An anti-BMCC1 antibody was prepared following the below-described procedures by using residues from 2074 to 2093 of BMCC1 protein (i.e., amino acid sequence: AKKPFSLKADGENPDILTHC, as shown by single-letter codes of amino acids; SEQ ID NO: 23; synthetic peptide by Medical & Biological Laboratories CO., LTD.) as an antigenic peptide.
- residues from 2074 to 2093 of BMCC1 protein i.e., amino acid sequence: AKKPFSLKADGENPDILTHC, as shown by single-letter codes of amino acids; SEQ ID NO: 23; synthetic peptide by Medical & Biological Laboratories CO., LTD.
- a rabbit Japanese white rabbit was immunized with the antigenic peptide, and a booster immunization was given.
- whole blood was collected and an antibody component which specifically recognized the antigenic peptide was purified using a column in which antigenic peptide was solid-phased. Specificity of the antibody was confirmed by an ELISA analysis using the antigenic peptide.
- the antibody component thus obtained was used as an anti-BMCC1 antibody in the following experiment.
- siRNA was introduced into human prostate cancer cell line LNCaP by a lipofection method (HiPerfect, product of QIAGEN), and the cells were cultured for 48 hours. A total RNA extracted from the cultured cells was used for cDNA synthesis, and semiquantitative RT-PCR was carried out ( FIG. 8 ).
- siRNA for BMCC1 As siRNA for BMCC1, the siRNA having the following sequence was designed and purchased from Integrated DNA Technologies, Inc.
- DD3 siRNA1 SEQ ID NOS:11 and 12
- DD3 siRNA3 SEQ ID NOS: 15 and 16
- DD3 siRNA4 SEQ ID NOS: 30 and 31 was used as siRNA for DD3.
- a DD3 (F3/R) primer set (SEQ ID NOS: 4 and 10) was used as a primer for detecting DD3, A BMCC1N (BNF2/BNR2) primer set (SEQ ID NOS: 1 and 2) and a BMCC1C (kiaa0367F/R) primer set (SEQ ID NOS: 8 and 9) were used as primers for detecting BMCC1, a PRUNE2 (BNF2/PRUNE2R1) primer set (SEQ ID NOS: 1 and 3) was used as a primer for detecting PRUNE2, a Caspase-3 (F/R) primer set (refer to Patent Document 1) was used as a primer for detecting Caspase-3, a PSA (F/R) primer set (SEQ ID NOS: 32 and 33) was used as a primer for detecting PSA, an ADR (F/R) primer set (SEQ ID NOS: 34 and 35) was used as a primer for detecting ADR, and a GAPDH1 (F/
- BMCC1 protein expression in cells in which DD3 expression or BMCC1 expression was suppressed was then confirmed by immunostaining and Western blotting using the anti-BMCC antibody ( FIGS. 9 and 10 ).
- Procedures of the immunostaining are as follows. Cells which were left for 48 hours after introduction of siRNA were fixed with 10% formalin for 15 minutes at room temperature, and treated with PBS containing 0.1% TritonX for 10 minutes at room temperature. After that, the cells were treated with the anti-BMCC1 antibody (1/500 dilution) for 3 hours at room temperature, and then with an anti-rabbit antibody labeled with Alexa488 (product of Molecular Probes, Inc., 1/1000 dilution) for 2 hours at room temperature.
- Alexa488 product of Molecular Probes, Inc., 1/1000 dilution
- BMCC1 protein in the LNCaP cells 48 hours after introduction of siRNA is shown in FIG. 9 (nuclei: blue, BMCC1: green, Cy3-siRNA: red).
- Procedures of the Western blot are as follows. A total extraction solution of the cells which were left for 48 hours after introduction of siRNA was separated by a SDS-page and transferred to a PVDF membrane (product of Millipore Corporation), followed by treatment with the anti-BMCC1 antibody (1/500 dilution) for 3 hours at room temperature and with an anti-rabbit antibody labeled with HRP (product of Zymed Laboratories, Inc., 1/1500 dilution) for 2 hours at room temperature. The membrane was subjected to color development using ECL (product of GE Healthcare), and exposed to an X-ray film (product of Fujifilm Corporation) for detection. A Western blot image of BMCC1 protein in the LNCaP cells into which siRNA for DD3 was introduced is shown in FIG. 10 .
- BMCC1 expression was confirmed in the LNCaP cells in which DD3 expression was suppressed by RT-PCR ( FIG. 8 ).
- BMCC1 expression was confirmed to be enhanced at the protein level as well by immunostaining and Western blotting using the anti-BMCC1 antibody ( FIGS. 9 and 10 ).
- cell viability was suppressed in the LNCaP cells in which DD3 expression was suppressed ( FIG. 11 ).
- LNCaP cells into which siRNA for DD3 was introduced were treated with DMSO (product of Nacalai Tesque, Inc.) or cisplatin, CDDP (product of SIGMA Corporation) for 48 hours, and observed under a microscope (product of Leica Microsystems) ( FIG. 12 ). Also, viability of the cells 48 hours after siRNA introduction was measured using a WST-8 kit ( FIG. 13 ). Apoptotic cells were detected by a TUNEL assay kit (product of F.
- FIGS. 12 to 14 a sensitivity of the LNCaP cells in which DD3 expression was suppressed to an anti-cancer agent, cisplatin, was increased ( FIGS. 12 to 14 ). That is, effects of suppressing viability ( FIGS. 12 and 13 ) and promoting apoptosis ( FIG. 14 ) of prostate cancer cells by cisplatin were enhanced additively and/or synergistically by suppressing DD3 expression.
- LNCaP cells were treated with DMSO or CDDP for 48, 72 hours in RPMI media containing 5% FBS containing androgen at a low concentration (product of Invitrogen Corporation), and viability of the cells was measured using a WST-8 kit ( FIG. 15 ).
- LNCaP cells into which siRNA was introduced were treated with DMSO or CDDP (product of SIGMA Corporation) for 48 hours in RPMI media containing 5% FBS containing androgen at a low concentration, and viability of the cells was measured using a WST-8 kit ( FIG. 16 ).
- DD3 suppressed BMCC1 gene expression and promoted cancer progression was strongly suggested based on a finding that DD3 expression was enhanced in androgen-dependent cancer cells, which corresponded to early-stage prostate cancer, while BMCC1 gene expression was suppressively regulated as prostate cancer progressed ( FIG. 4 ) and a finding that BMCC1 gene expression was enhanced by suppression of DD3 expression ( FIGS. 6 and 7 ).
- BMCC1 has a function to promote apoptosis and acts as a cancer suppressor gene on one side
- a method found by Examples of the present application which directs to recovering BMCC1 expression by suppression of DD3 expression by siRNA, is considered effective for cancer treatment.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
- The present invention relates to a cancer marker and a therapeutic agent for cancer.
- Prostate cancer is the cancer which has the highest prevalence among males in Europe and the U.S. Also in Japan, the number of patients with prostate cancer is increasing year by year along with westernization of dietary habits and aging of the population. Prostate cancer includes an androgen-dependent tumor and an androgen-independent tumor. Generally, proliferation of prostate cancer cells is stimulated by androgen; therefore, in treatment of unresectable progressive prostate cancer, androgen blockade therapy, which inhibits production and function of androgen, is frequently implemented. Early-stage prostate cancer often responds to androgen blockade therapy because most of it is androgen dependent. However, once it has progressed to an androgen-independent tumor, androgen blockade therapy cannot be implemented, and even more, no good treatment method exists. In view of the foregoing, effective treatment for androgen-independent tumor is needed.
- A BMCC1 gene is a novel gene discovered as a result of a research project "a comprehensive gene expression analysis in tumor tissue using a cDNA microarray derived from a tumor of neuroblastoma and identification of a cancer suppressor gene, an oncogene, and a prognosis-determining factor using the same" in Chiba Cancer Center, by which a strong correlation between BMCC1 gene expression and prognosis of neuroblastoma was reported (Patent Document 1 and Non-Patent Document 1). However, involvement of the BMCC1 gene in prostate cancer is not known.
- Patent Document 1: Japanese Patent Laid-Open No.
2003-061672 - Non-Patent Document 1: Machida, T. et al., (2006), Oncogene, Vol. 25, p1931-1942
- If molecular mechanisms of a gene involved in cancer are elucidated and a therapeutic medicine based on a novel mechanism can be developed, a range of options for cancer diagnosis and cancer treatment can be expanded. Accordingly, an object of the present invention is to provide a novel cancer marker. Another object of the present invention is to provide a novel therapeutic agent for cancer.
- The present inventors found that the BMCC1 gene was expressed in tissues other than neural tissue in which expression of the gene had been previously known, and BMCC1 gene expression in prostate cancer, lung cancer, gastric cancer, bladder cancer, and uterine cancer was reduced compared with a normal specimen based on experimental results of an expression analysis of cancer tissue. The present inventors further found that BMCC1 gene expression was enhanced when DD3 expression was suppressed by DD3-specific siRNA. Combined with the findings that DD3 expression is enhanced in early-stage prostate cancer, while BMCC1 expression is suppressed in late-stage prostate cancer, the aforementioned findings suggest a possibility that DD3 inhibits BMCC1 gene expression and promotes cancer progression. The present inventors completed the present invention based on the findings as described above.
- That is to say, the present invention provides a method for detecting cancer using a level of BMCC1 gene expression in a specimen as an indication, in which the cancer is selected from the group consisting of bladder cancer, and uterine cancer.
- Furthermore, the method for detecting cancer according to the present invention is characterized by including a step of measuring a level of BMCC1 gene expression in a specimen with a suspicion of cancer, a step of comparing the level of BMCC1 gene expression with levels of BMCC1 gene expression in a normal specimen and in a cancer specimen, and a step of judging the specimen suspect of being affected by cancer as cancer in a case where the level of BMCC1 gene expression in the specimen with a suspicion of cancer is (i) lower than the level of BMCC1 gene expression in the normal specimen, (ii) the same level as the level of BMCC1 gene expression in the cancer specimen, or falls into both (i) and (ii). The specimen is preferably a cell or a piece of tissue.
- The method for detecting cancer according to the present invention is based on findings discovered by the inventors of the present application that the BMCC1 gene is expressed in tissues other than neural tissue in which expression of the gene has been previously known, and BMCC1 gene expression in prostate cancer, lung cancer, gastric cancer, bladder cancer, and uterine cancer is reduced compared with a normal tissue. Provision of a cancer marker for a method for detecting cancer is made possible by the above findings.
- The present invention provides siRNA which targets DD3, in which the siRNA is double-stranded siRNA comprising a pair of oligonucleotides of any one of (a) to (d) as described below;
- (a) an oligonucleotide comprising a sequence described in SEQ ID NO: 11 and an oligonucleotide comprising a sequence described in SEQ ID NO: 12;
- (b) an oligonucleotide comprising a sequence described in SEQ ID NO: 13 and an oligonucleotide comprising a sequence described in SEQ ID NO: 14;
- (c) an oligonucleotide comprising a sequence described in SEQ ID NO: 15 and an oligonucleotide comprising a sequence described in SEQ ID NO: 16; and
- (d) an oligonucleotide comprising a sequence described in SEQ ID NO: 30 and an oligonucleotide comprising a sequence described in SEQ ID NO: 31.
- The present disclosure further provides a therapeutic agent for cancer containing the siRNA described above as an active ingredient. The cancer described above is preferably selected from the group consisting of prostate cancer, lung cancer, gastric cancer, bladder cancer, and uterine cancer, among which it is more preferably prostate cancer.
- DD3 is a non-coding RNA which is known as a prostate cancer marker. DD3 is encoded by q21.13 of chromosome 9, and interestingly, it is inserted in reverse orientation in
intron 6 of the BMCC1 gene (FIG. 1 ), based on which the inventors of the present application established a hypothesis that DD3 suppressively regulates BMCC1 gene expression. The hypothesis was examined in Examples of the present application. In fact, the inventors of the present application found for the first time that BMCC1 gene expression was enhanced and viability of cancer cells is more effectively suppressed by suppression of DD3 expression by DD3-specific siRNA. The present invention is based on the above-described findings, and delay in cancer progression and improvements in symptoms of cancer can be expected by a therapeutic agent of the present invention. - The present invention provides a therapeutic agent for cancer, which further contains an anti-cancer agent. The anti-cancer agent is preferably cisplatin. Also, the present invention provides a therapeutic agent for cancer, which further contains an anti-androgen agent. The cancer is preferably prostate cancer.
- The present invention is based on a finding that viability of cancer cells is more effectively suppressed when treatment with cisplatin and/or removal of androgen are/is employed concurrently in addition to inhibition of DD3 expression, and delay in cancer progression, improvements in symptoms of cancer, and the like can be expected by the therapeutic agent of the present invention.
-
-
FIG. 1 schematically shows chromosomal locations of human BMCC1 gene, PRUNE2 gene, and DD3 gene; -
FIG. 2 shows the results of expression of BMCC1 gene, PRUNE2 gene, and DD3 gene in human normal tissue as examined by semiquantitative RT-PCR; -
FIG. 3 shows the results of expression of BMCC1 gene and DD3 gene in a matched pair of human normal tissue and cancer tissue as examined by semiquantitative RT-PCR, in which N means a sample derived from normal tissue, T means a sample derived from tumor cell tissue, and ND means Not Determined; -
FIG. 4 shows the results of expression of BMCC1 gene, PRUNE2 gene, and DD3 gene in a prostate cancer cell line as examined by semiquantitative RT-PCR; -
FIG. 5 schematically shows a structure of DD3 non-coding RNA (i.e., ncRNA) and a location of siRNA with respect to DD3; -
FIG. 6 shows the results of expression of BMCC1 gene, PRUNE2 gene, and DD3 gene in a prostate cancer cell line into which siRNA for DD3 was introduced as examined by semiquantitative RT-PCR; -
FIG. 7 (A) shows the results of expression of BMCC1 gene, PRUNE2 gene, and DD3 gene in an LNCaP cell line into which siRNA for DD3 was introduced as examined by semiquantitative RT-PCR, and (B) showscells 48 hours after introduction of siRNA; -
FIG. 8 shows the results of expression of BMCC1 gene, PRUNE2 gene, and DD3 gene in LNCaP cells into which siRNA for DD3 was introduced as examined by semiquantitative RT-PCR; -
FIG. 9 is an immunostaining image of BMCC1 protein inLNCaP cells 48 hours after introduction of siRNA; -
FIG. 10 is a Western blot image of BMCC1 protein in LNCaP cells into which siRNA for DD3 was introduced; -
FIG. 11 shows a relative cell viability rate ofLNCaP cells 48 hours after introduction of siRNA; -
FIG. 12 showsLNCaP cells 48 hours after introduction of siRNA in the presence of cisplatin; -
FIG. 13 shows a relative cell viability rate ofLNCaP cells 48 hours after introduction of siRNA in the presence of cisplatin; -
FIG. 14 showsapoptotic cells 48 hours after introduction of siRNA in the presence of cisplatin; -
FIG. 15 shows a relative cell viability rate of LNCaP cells in the presence of cisplatin; and -
FIG. 16 shows a relative cell viability rate ofLNCaP cells 48 hours after introduction of siRNA in the presence of cisplatin. - Preferred embodiments of the present invention are described in detail hereinbelow.
- The BMCC1 gene, which stands for BCH motif-containing molecule at the carboxyl terminal region 1, is a gene identified by the inventors of the present application as a gene involved in determination of prognosis of neuroblastoma in Japanese Patent Laid-Open No.
2003-061672 FIG. 1 schematically shows chromosomal locations of human BMCC1 gene, PRUNE2 gene, and DD3 gene. As shown inFIG. 1 , the BMCC1 gene locates in q21.13 of human chromosome 9. Also, in the same chromosomal region, a PRUNE 2 gene is present (GenBank Accession No. NM138818). Further, it was found that the DD3 gene was inserted in reverse orientation inintron 6 of the BMCC1 gene. Namely, a sequence of the DD3 gene was perfectly complementary to a part ofintron 6 of the BMCC1 gene. DD3 encoded by the DD3 gene (GenBank Accession No. AF103907) is a non-coding RNA (i.e., ncRNA), which is also called a prostate cancer antigen (i.e., PCA). It is known as a prostate cancer marker; however, involvement of DD3 in a mechanism of tumorigenesis has not been elucidated. - Based on the findings that the sequence of DD3 gene is complementary to the sequence of BMCC1 gene and that BMCC1 gene expression and DD3 expression had a tendency toward an inverse correlation as suggested by the results from Examples 1 and 2 as shown below, the present inventors proposed a hypothesis that an inhibitory mechanism of BMCC1 expression by DD3 existed as an inhibitory mechanism of BMCC1 function. Findings supportive of the hypothesis were obtained by Examples 3-6 as shown below. Namely, because BMCC 1 gene expression was enhanced by suppression of DD3 expression, it was strongly suggested that DD3 suppressively regulated BMCC1 gene expression. Also, it was elucidated that BMCC1 gene expression could be enhanced and viability of cancer cells could be suppressed by suppression of DD3 expression.
- Most of the early-stage prostate cancer is androgen dependent so that it is often cured with androgen blockade therapy. However, prostate cancer recurred thereafter cannot be treated with androgen blockade therapy, and even more, no good treatment method exists. A fact that a number of androgen-dependent prostate cancer is cured with androgen blockade therapy suggests that a gene cluster induced by androgen is involved in oncogenic transformation of the prostate gland. Findings that DD3 expression is enhanced in the early-stage prostate cancer and BMCC1 expression is inhibited in the late-stage prostate cancer, which were elucidated for the first time by the present invention, suggest a possibility that DD3 inhibits BMCC1 gene expression and promotes cancer progression. Accordingly, if BMCC1 gene expression is enhanced by specifically suppressing DD3 expression, an effect is expected from the standpoint of cancer treatment and delay in cancer progression. Furthermore, as shown in Examples 7 and 8 below, it has been found that viability of cancer cells can be more effectively suppressed when treatment with cisplatin and/or removal of androgen are/is employed concurrently in addition to suppression of DD3 expression. Accordingly, it was suggested that combination use of the therapeutic agent of the present invention and another treatment method which employs an anti-cancer agent, an anti-androgen agent, and the like was effective.
- A method for detecting cancer according to the present embodiment is described. The method for detecting cancer according to the present embodiment is based on a level of BMCC1 gene expression as an indication. Using the BMCC1 gene as a cancer marker, the method detects a cancer cell or cancer tissue based on the finding of the present invention that there is a correlation between a low level of BMCC1 gene expression and cancer. Furthermore, the method for detecting cancer according to the present embodiment includes a step of measuring a level of BMCC1 gene expression in a specimen with a suspicion of cancer, a step of comparing the level of BMCC1 gene expression with levels of BMCC1 gene expression in a normal specimen and in a cancer specimen, and a step of judging the specimen suspect of being affected by cancer as cancer in a case where the level of BMCC 1 gene expression in the specimen with a suspicion of cancer is (i) lower than BMCC1 gene expression in the normal specimen, (ii) the same level as the level of BMCC1 gene expression in the cancer specimen, or falls into both (i) and (ii).
- A preferred subject can be a human. The cancer is preferably selected from the group consisting of prostate cancer, lung cancer, gastric cancer, bladder cancer, and uterine cancer, among which it is more preferably prostate cancer. The specimen is preferably a cell or a piece of tissue which is susceptible to onset of cancer to be examined.
- A level of gene expression refers to a level of mRNA expression, which is a transcription product of the gene, and/or a level of protein expression, which is a translation product of the mRNA. A level of mRNA expression can be measured by a measurement system publicly known to a person skilled in the art, and specific examples thereof include a semi-quantitative RT-PCR method, a quantitative real-time RT-PCR method, a quantitative Northern blotting method, and a quantitative ribonuclease protection method. A level of protein expression can be measured by a measurement system publicly known to a person skilled in the art, and examples thereof include a quantitative Western blotting method and an ELISA method. Using levels of mRNA and/or protein expression of GAPDH, which is a housekeeping gene, beta-actin, and the like as a control, the level of expression of an objective gene such as a BMCC1 gene is standardized. Also, levels of objective gene expression and/or control gene expression in an aliquot derived from a plurality of samples and/or an identical sample obtained from an identical subject are measured, and the level of expression can be obtained from a mean value of each of them. Gene expression can be quantitatively measured by using these methods.
- Primers and probes for detecting BMCC1 mRNA can be designed by a method commonly known to a person skilled in the art. As for primers for detecting BMCC1 mRNA, a BMCC1 (BNF2/BNR2) primer set (SEQ ID NOS: 1 and 2), a kiaa0367F/R primer set (SEQ ID NOS: 8 and 9), and the like are exemplified; however, the primers are not limited to these examples. Also, an antibody, an antibody fragment, and the like for detecting BMCC 1 protein can be prepared by a method commonly known to a person skilled in the art. As for a usable anti-BMCC1 antibody, an antibody raised against an epitope containing residues from 2074 to 2093 of BMCC1 protein (i.e., amino acid sequence: AKKPFSLKADGENPDILTHC, as shown by single-letter codes of amino acids; SEQ ID NO: 23), an antibody raised against an epitope containing residues from 3068 to 3088 of BMCC1 protein (i.e., amino acid sequence: YNDPEMSSMEKDIDLKLKEKP (as shown by single-letter codes of amino acids; SEQ ID NO: 36), an antibody raised against an epitope containing residues from 1733 to 1753 of BMCC1 protein (i.e., amino acid sequence: KSENIYDYLDSSEPAENENKSNPFC (as shown by single-letter codes of amino acids; SEQ ID NO: 37), a commercially available antibody, and the like are preferably used; however, the antibody is not limited to these examples.
- The level of BMCC1 gene expression in a normal specimen can be obtained by statistically processing a measurement value of a level of expression which is obtained from a specimen derived from a plurality of normal tissue which are not oncogenically transformed obtained from single or a plurality of subject(s) (a control group). Also, the level of BMCC1 gene expression in a cancer specimen can be obtained by statistically processing measurement values of a level of expression obtained from specimens derived from a plurality of cancer tissues obtained from single or a plurality of patient(s) of cancer (a disease group). As for detection of cancer, specifically, (i) a specimen with a suspicion of cancer is judged as a cancer specimen in a case where the level of BMCC1 gene expression in the specimen with a suspicion of cancer is lower than the level of BMCC1 gene expression in the normal specimen, and/or in a case where, in comparison with the level of expression obtained from the control group, the level of BMCC1 gene expression statistically corresponds to a range lower than a distribution range of the control group. Also, (ii) a specimen with a suspicion of cancer is judged as a cancer specimen in a case where the level of BMCC1 gene expression in the specimen with a suspicion of cancer is the same level as the level of BMCC1 gene expression in the cancer specimen, and/or in a case where, in comparison with the level of expression obtained from the disease group, the level of BMCC1 gene expression statistically corresponds to a distribution range of the disease group. Furthermore, a specimen with a suspicion of cancer is judged as a cancer specimen in a case where the level of BMCC1 gene expression in the specimen with a suspicion of cancer falls into both (i) and (ii).
- Therapeutic agent for cancer The siRNA which targets DD3 according to the present disclosure is double-stranded siRNA comprising a pair of oligonucleotides of any one of (a) to (d) as described below;
- (a) an oligonucleotide comprising a sequence described in SEQ ID NO: 11 and an oligonucleotide comprising a sequence described in SEQ ID NO: 12;
- (b) an oligonucleotide comprising a sequence described in SEQ ID NO: 13 and an oligonucleotide comprising a sequence described in SEQ ID NO: 14;
- (c) an oligonucleotide comprising a sequence described in SEQ ID NO: 15 and an oligonucleotide comprising a sequence described in SEQ ID NO: 16; and
- (d) an oligonucleotide comprising a sequence described in SEQ ID NO: 30 and an oligonucleotide comprising a sequence described in SEQ ID NO: 31.
- The term siRNA is an abbreviation for short interfering RNA, and refers to a double-stranded RNA having 10 or more base pairs which is obtained by artificial chemical synthesis or biochemical synthesis, or by synthesis inside a body of an organism, or by degradation of double-stranded RNA having approximately 40 or more bases inside a body. A length of siRNA is generally 10-30-base long, preferably approximately 15-25-base long, more preferably around 19-23-base long. The siRNA usually has a structure of 5'-phosphate and 3'-OH, and approximately 2 bases overhang at the 3'-end thereof.
- Administration of siRNA to a cell can specifically inhibit DD3 expression by an RNA interference effect. That is, when siRNA is introduced inside a cell, protein specific to the siRNA binds thereto to form a RISC (i.e., RNA-induced-silencing-complex). The complex recognizes and binds to mRNA having a sequence identical to the siRNA, and cleaves the mRNA at a center of the siRNA by an RNase III-like enzymatic activity. As described above, siRNA can inhibit expression of a target gene (i.e., DD3 gene in the present invention) by degrading mRNA having a sequence homologous to the siRNA. A phenomenon described above is called RNA interference (RNAi). The RNAi phenomenon is a phenomenon observed in nematodes, insects, protozoa, hydras, plants, and vertebrates (including mammals).
- Also, in another embodiment, siRNA specific to DD3 other than the ones described above can be used. Furthermore, shRNA (i.e., short hairpin RNA) and dsRNA (i.e., double strand RNA) capable of producing the siRNA, or an expression vector which can express the shRNA and the dsRNA can be employed. When the shRNA, the dsRNA, or the expression vector thereof is administered to a cell, siRNA is produced inside the cell. A promoter of an RNA polymerase III (Pol III) which participates in a transcription system of U6RNA or H1RNA can be used as a promoter for the expression vector of the RNA.
- Further, in another embodiment, the siRNA described above can be RNA, RNA : DNA hybrid, or a modified nucleic acid (RNA and DNA). Specific examples of the modified nucleic acid(s) can be sulfur derivatives and thiophosphate derivatives of nucleic acid(s), as well as ones resistant to degradation of polynucleotide amide and oligonucleotide amide; however, the modified nucleic acid(s) are not limited to these examples.
- The therapeutic agent for cancer according to the present embodiment has the siRNA described above as an active ingredient. The therapeutic agent for cancer can contain the siRNA singly or 2 or more thereof in combination.
- In a preparation of the therapeutic agent for cancer according to the present invention, a pharmaceutically acceptable carrier can be added as needed in accordance with a conventional method. For example, it can be a surfactant, an excipient, a colorant, a scent, a preservative, a stabilizer, a buffer, a suspending agent, a tonicity agent, a binder, a disintegrant, a lubricant, a fluidity promoter, and a flavor; however, it is not limited to these examples, and a carrier which is ordinarily used can be employed as appropriate. Specific examples thereof can be light anhydrous silicic acid, lactose, crystalline cellulose, mannitol, starch, carmellose calcium, carmellose sodium, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, polyvinyl acetal diethylaminoacetate, polyvinylpyrrolidone, gelatin, medium-chain fatty acid triglyceride, polyoxyethylene
hardened castor oil 60, sucrose, carboxymethylcellulose, corn starch, an inorganic salt, and the like. - Kinds of formulation of the therapeutic agent for cancer according to the present invention can be, for example, an oral agent such as a tablet, a pulverized agent, a pill, a powder, a granule, a fine granule, soft and hard capsules, a film-coated preparation, a pellet, a sublingual agent, and a paste, as well as a parenteral agent such as an injection, a suppository, a percutaneous agent, an ointment, a plaster, and a liquid preparation for external use, and a person skilled in the art can select a most suitable dosage form according to an administration route, a subject to be administered, and the like. A prepared product can contain 0.1 to 99.9% by weight of the siRNA described above as an active ingredient.
- Although a dose of the active ingredient of the therapeutic agent for cancer according to the present invention differs depending on a subject to be administered, a target organ, a symptom, a method of administration, and the like, a daily dose is generally, for example, approximately 0.1 mg to 1,000 mg, preferably approximately 1.0 to 100 mg, more preferably approximately 1.0 to 50 mg for a patient (supposed to weigh 60 kg) in a case of oral administration. In a case of parenteral administration, although a dose per administration differs depending on a subject to be administered, a target organ, a symptom, a method of administration, and the like, for example, it is convenient in a case of an injection, generally, for example, to administer at approximately 0.01 to around 30 mg, preferably at approximately 0.1 to around 20 mg, more preferably at approximately 0.1 to around 10 mg daily to a patient (supposed to weigh 60 kg) by an intravenous injection. However, the dose can ultimately be determined as appropriate based on judgment of a physician in consideration of a kind of dosage form, an administration method, age and weight of a patient, a patient's symptoms, and the like.
- The therapeutic agent for cancer according to the present invention is used for prevention and treatment of prostate cancer, lung cancer, gastric cancer, bladder cancer, uterine cancer, and the like, and it is preferably used for prevention and treatment of prostate cancer.
- In another embodiment, the therapeutic agent for cancer according to the present invention can be used in combination with an anti-cancer agent. The anti-cancer agent can be cisplatin, peplomycin, ifosfamide, tegafur/uracil, estramustine, docetaxel, gemcitabine, oxaliplatin, and the like, among which it is preferably cisplatin. Also, in another embodiment, the therapeutic agent for cancer according to the present invention can be used in combination with an anti-androgen agent. Furthermore, in another embodiment, the therapeutic agent for cancer according to the present invention can be used in combination with an anti-cancer agent and an anti-androgen agent.
- Preferred Examples of the present invention are described further in detail hereinbelow; however, the present invention is not limited to these Examples.
- Using a total RNA extracted from human normal tissue (product of Clontech Laboratories, Inc.), a semiquantitative RT-PCR was conducted following the below-described experimental procedures to examine mRNA expression of BMCC1 gene, PRUNE2 gene, and DD3 gene.
- Using SuperScript First-Strand Synthesis System for RT-PCR (product of Invitrogen Corporation), cDNA was synthesized following a protocol of the product. For cDNA synthesis, 2 µg of the total RNA and random primers (Random Hexamers, product of Invitrogen Corporation) were used.
- A PCR reaction was carried out with the following conditions.
-
- BMCC1;
- BNF2:5'- ctgaacgatgaagggaaactgtcgataacgc-3' (SEQ ID NO: 1) and
- BNR2:5'-cactgcctgccacggcttctgttg-3' (SEQ ID NO: 2)
- PRUNE2;
- BNF2 (SEQ ID NO: 1) and
- PRUNE2R1:5'- cacagcagatgttgaactccaggtgttc-3' (SEQ ID NO: 3) DD3;
- DD3F3:5'-ggtgggaaggacctgatgatac-3' (SEQ ID NO: 4) and
- DD3R3:5'-gcacagggcgaggctcatcgatg-3' (SEQ ID NO: 5)
- GAPDH1;
- GAPDH1F:5'-accacagtccatgccatcac-3' (SEQ ID NO: 6)
- GAPDH1R:5'-tccaccaccctgttgctgta-3' (SEQ ID NO: 7)
-
cDNA 1 µl 10x rTaq Buffer 1 µl 2.5 mM dNTPs 1 µl Forward primers (10 µM) 0.5 µl Reverse primers (10 µM) 0.5 µl Sterilized water 6 µl rTaq 0.1 µl Total volume 10 µl - A tube containing a reaction solution of the above composition was set in a thermal cycler (Gene Amp@ PCR System 9700, product of Applied Biosystems). In a case of a BMCC1 (BNF2/BNR2) primer set (SEQ ID NOS: 1 and 2), a sample was heated to 95°C for 2 minutes, after which a cycle containing 95°C for 15 seconds → 59°C for 15 seconds → 72°C for 20 seconds was repeated 38 times, and the sample was kept at 72°C for 6 minutes. In a case of a PRUNE2 (BNF2/PRUNE2R1) primer set (SEQ ID NOS: 1 and 3), a sample was heated to 95°C for 2 minutes, after which a cycle containing 95°C for 15 seconds → 59°C for 15 seconds → 72°C for 20 seconds was repeated 38 times, and the sample was kept at 72°C for 7 minutes. In a case of a DD3 (F3/R3) primer set (SEQ ID NOS: 4 and 5), a sample was heated to 95°C for 2 minutes, after which a cycle containing 95°C for 15 seconds → 63°C for 15 seconds → 72°C for 20 seconds was repeated 38 times, and the sample was kept at 72°C for 6 minutes. In a case of a GAPDH 1 (F1/R1) primer set (SEQ ID NOS: 6 and 7), a sample was heated to 95°C for 2 minutes, after which a cycle containing 95°C for 15 seconds → 58°C for 15 seconds → 72°C for 20 seconds was repeated 28 times, and the sample was kept at 72°C for 6 minutes. The PCR products thus obtained were subjected to electrophoresis on 2% agarose gel and detected by ethidium bromide (product of SIGMA Corporation).
- The results of BMCC1 gene, PRUNE2 gene, and DD3 gene expression in human normal tissue as examined by a semiquantitative RT-PCR are shown in
FIG. 2 . As a result, BMCC1 expression was confirmed in tissues other than the neural system in which BMCC1 expression had been reported. Also, DD3 was expressed prominently in the prostate gland. - In view of the foregoing, BMCC1 expression in various cancer was examined using a matched pair of normal tissue and cancer tissue derived from patients of lung cancer (2 patients), gastric cancer (2 patients), bladder cancer (4 patients), uterine cancer (1 patient), and prostate cancer (2 patients) by an RT-PCR method.
- The method described in Example 1 was employed except that a total RNA extracted from a matched pair of human normal tissue and cancer tissue (product of Clontech Laboratories, Inc.) was used and a kiaa0367F/R primer set (SEQ ID NOS: 8 and 9) was used in addition to a BNF2/BNR2 primer set (SEQ ID NOS: 1 and 2) as a primer for detecting BMCC1.
-
- BMCC1;
- kiaa0367F:5'-gaagcctctggtccagtcag-3' (SEQ ID NO: 8) and
- kiaa0367R:5'-cttcggccgtatattctgga-3' (SEQ ID NO: 9)
- A PCR reaction using a BMCC1 (kiaa0367F/R) primer set was carried out by heating the sample to 95°C for 2 minutes and repeating a cycle containing 95°C for 15 seconds → 61°C for 15 seconds → 72°C for 20 seconds 35 times, followed by keeping the sample at 72°C for 6 minutes.
- The results of expression of BMCC1 gene and DD3 gene in the matched pair of human normal tissue and cancer tissue as examined by a semiquantitative RT-PCR are shown in
FIG. 3 . As a result, BMCC1 expression was found to be reduced in a cancer site compared with a normal site, which suggested that a functional inhibition of BMCC1 in cancer was caused by reduction in its expression. Also, it was found that DD3 expression was enhanced in a plurality of cancer tissues. - To verify a possibility that DD3 suppressively regulates BMCC1 gene expression, expression of BMCC1 gene, PRUNE2 gene, and DD3 gene was confirmed in a cell line established from prostate cancer according to the following method.
- An LNCaP cell line, a PC3 cell line, and a Du145 cell line, all of which were cell lines established from prostate cancer, were provided by Dr. Ueda (Director of Department of Urology, Chiba Cancer Center) and used in this examination. The LNCaP cell is an androgen dependent cell line, while the PC3 cell and the Du145 cell are androgen independent cell lines. Properties of these cell lines are shown in Table 1. Also, a SK-N-BE cell line, which was a neuroblastoma cell line, was used as a control.
[Table 1] Cell line Androgen sensitivity DD3 mRNA TP53* Status LNCaP Androgen dependent (Androgen sensitive) Positive Wild type PC3 Androgen independent Negative Mutant (138 frameshift 169 stop codon) Du145 Androgen independent Negative Mutant (P223L) *TP53: tumor protein p53 (GENEBANK ACCESSION No. NM000546) - Cultured cells of each cell line (80% confluent in a 100 mm dish) were collected and suspended in 1 mL of ISOGEN (product of Nippon Gene Co., Ltd.), from which a total RNA was purified following a protocol of the product. The methods described in Example 1 were employed for cDNA synthesis and PCR reactions except that a F3/R primer set (SEQ ID NOS: 4 and 10) was used in addition to a F3/R3 primer set (SEQ ID NOS: 4 and 5) as a primer for detecting DD3.
-
- DD3;
- F3 (SEQ ID NO: 4) and
- DD3R:5'-tcctgcccatcctttaagg-3' (SEQ ID NO: 10)
- A PCR reaction using a DD3 (F3/R) primer set was carried out by heating the sample to 96°C for 5 minutes and repeating a cycle containing 96°C for 30 seconds → 62°C for 60 seconds 35 times.
- The results of expression of BMCC1 gene, PRUNE2 gene, and DD3 gene in a prostate cancer cell line as examined by a semiquantitative RT-PCR are shown in
FIG. 4 . As a result, DD3 was confirmed to be highly expressed in androgen dependent LNCaP cells. Interestingly, it was elucidated that BMCC1 was highly expressed in LNCaP cells as well, while BMCC1 expression was reduced in PC3 cells and Du145 cells, which may correspond to prostate cancer with higher malignancy. These results suggest that BMCC1 gene expression is suppressively regulated as prostate cancer progresses. - In order to examine an effect of suppression of DD3 expression by siRNA for DD3 on BMCC1 gene expression, a semiquantitative RT-PCR was carried out using a total RNA extracted from prostate cancer cell lines (an LNCaP cell line and a PC3 cell line) into which siRNA was introduced.
- Three kinds of siRNA for DD3 were designed and purchased from Integrated DNA Technologies, Inc. A structure of DD3 ncRNA and locations of siRNA for DD3 are shown schematically in
FIG. 5 . Sequences of the three kinds of siRNA to DD3 (i.e., DD3 siRNA 1, 2, and 3) are as follows; - DD3 siRNA 1:5'-ggaaccaagauacaaagaacucuga-3' (SEQ ID NO: 11) and
- 5'-ucagaguucuuuguaucuugguuccuu-3' (SEQ ID NO: 12)
- DD3 siRNA2:5'-ucacuagaaacagcaagaugacaat-3' (SEQ ID NO: 13) and
- 5'-auugucaucuugcuguuucuagugaug-3' (SEQ ID NO: 14)
- DD3 siRNA3:5'-ggcauacuauaucaacuuugauuct-3' (SEQ ID NO: 15) and
- 5'-agaaucaaaguugauauaguaugccaa 3' (SEQ ID NO: 16)
- control siRNA:sense strand 5'-cuuccucucuuucucucccuuguga-3' (SEQ ID NO: 17) and antisense strand 5'-ucacaagggagagaaagagaggaagga-3' (SEQ ID NO: 18)
- HiPerfect, a product of QIAGEN, was used for transduction of siRNA. Cultured cells of each cell line were transduced with 5 nM of each siRNA according to a protocol of the product. The cultured cells were collected 48 hours after transduction and a total RNA was purified according to a protocol of the product. The methods described in Examples 1 to 4 were used for cDNA synthesis and PCR reactions except that, as a primer for detecting DD3, a DD3 (F3/R) primer set (SEQ ID NOS: 4 and 10) was used in
FIG. 6 , and a DD3 (taqF4/taqR2) primer set (SEQ ID NOS: 21 and 22) was used inFIG. 7 . As a primer for detecting BMCC1, a BMCC1 (BNF2/BNR2) primer set (SEQ ID NOS: 1 and 2) was used, and as a primer for detecting PRUNE2, a PRUNE2 (BNF2/PRUNE2R1) primer set (SEQ ID NOS: 1 and 3) was used, and as a primer for detecting GAPDH1, a GAPDH1 (F/R) primer set (SEQ ID NOS: 6 and 7) was used. -
- DD3;
- taqF4: 5'-cacagagatccctgggagaaat-3' (SEQ ID NO: 21) and
- taqR2:5'-ctgcccatcctttaaggaacac-3' (SEQ ID NO: 22)
-
cDNA 1 µl 10x LA-Taq Buffer 1 µl 2.5 mM dNTPs 1 µl 2.5 mM MgCl2 1 µl Forward primers (10 µM) 0.5 µl Reverse primers (10 µM) 0.5 µl Sterilized water 5 µl LA-Taq 0.1 µl Total volume 10 µl - To carry out a PCR reaction using a DD3 (taqF4/taqR2) primer set, a tube containing a reaction solution of the above composition containing LA-Taq (product of Takara Bio Inc.) was set in a thermal cycler (Gene Amp@ PCR System 9700, product of Applied Biosystems) and heated to 95°C for 2 minutes. After that, a cycle containing 95°C for 15 seconds → 60°C for 15 seconds → 72°C for 20 seconds was repeated 35 times, and the sample was kept at 72°C for 7 minutes.
- The results of expression of BMCC1 gene, PRUNE2 gene, and DD3 gene in a prostate cancer cell line into which siRNA for DD3 was introduced as examined by a semiquantitative RT-PCR are shown in
FIGS. 6 and7 . As a result, any of the siRNA was confirmed to inhibit DD3 expression (FIGS. 6 and7 ). It was elucidated that in cells in which DD3 expression was inhibited, BMCC1 expression was enhanced in both of the LNCaP cells and the PC3 cells regardless of androgen dependency (FIG. 6 ). - An anti-BMCC1 antibody was prepared following the below-described procedures by using residues from 2074 to 2093 of BMCC1 protein (i.e., amino acid sequence: AKKPFSLKADGENPDILTHC, as shown by single-letter codes of amino acids; SEQ ID NO: 23; synthetic peptide by Medical & Biological Laboratories CO., LTD.) as an antigenic peptide.
- A rabbit (Japanese white rabbit) was immunized with the antigenic peptide, and a booster immunization was given. After the eighth immunization, whole blood was collected and an antibody component which specifically recognized the antigenic peptide was purified using a column in which antigenic peptide was solid-phased. Specificity of the antibody was confirmed by an ELISA analysis using the antigenic peptide. The antibody component thus obtained was used as an anti-BMCC1 antibody in the following experiment.
- In a similar manner to Example 5, siRNA was introduced into human prostate cancer cell line LNCaP by a lipofection method (HiPerfect, product of QIAGEN), and the cells were cultured for 48 hours. A total RNA extracted from the cultured cells was used for cDNA synthesis, and semiquantitative RT-PCR was carried out (
FIG. 8 ). - As siRNA for BMCC1, the siRNA having the following sequence was designed and purchased from Integrated DNA Technologies, Inc.
- siBMCC1-1: 5'-ggagaaggauauugacuugaagctg-3' (SEQ ID NO: 24) and 5'-cagcuucaagucaauauccuuucuccau-3' (SEQ ID NO: 25)
- siBMCC1-2: 5'-ggaguaucaggaagcaaaucaggta-3' (SEQ ID NO: 26) and 5'-uaccugauuugcuuccugauacuccaa-3' (SEQ ID NO: 27)
- siBMCC1-3: 5'-cccagugagauaaacaaugaagcag-3' (SEQ ID NO: 28) and 5'-cugcuucauuguuuaucucacugggug-3' (SEQ ID NO: 29)
- Also, DD3 siRNA1 (SEQ ID NOS:11 and 12), DD3 siRNA3 (SEQ ID NOS: 15 and 16) and DD3 siRNA4 (SEQ ID NOS: 30 and 31) was used as siRNA for DD3.
- DD3 siRNA4:5'-ggaguuagauuuaugcauauugugguu-3' (SEQ ID NO: 30) and 5'-ccacaauaugcauaaaucuaacucc-3' (SEQ ID NO: 31)
- A DD3 (F3/R) primer set (SEQ ID NOS: 4 and 10) was used as a primer for detecting DD3, A BMCC1N (BNF2/BNR2) primer set (SEQ ID NOS: 1 and 2) and a BMCC1C (kiaa0367F/R) primer set (SEQ ID NOS: 8 and 9) were used as primers for detecting BMCC1, a PRUNE2 (BNF2/PRUNE2R1) primer set (SEQ ID NOS: 1 and 3) was used as a primer for detecting PRUNE2, a Caspase-3 (F/R) primer set (refer to Patent Document 1) was used as a primer for detecting Caspase-3, a PSA (F/R) primer set (SEQ ID NOS: 32 and 33) was used as a primer for detecting PSA, an ADR (F/R) primer set (SEQ ID NOS: 34 and 35) was used as a primer for detecting ADR, and a GAPDH1 (F/R) primer set (SEQ ID NOS: 6 and 7) was used as a primer for detecting GAPDH1.
-
- PSA;
- F:5'-gcctctcgtggcagggcagt-3' (SEQ ID NO: 32) and
- R:5'-gggtgaacttgcgcacacac-3' (SEQ ID NO: 33)
- ADR;
- F:5'-tcaaaagagccgctgaagggaaaca-3' (SEQ ID NO: 34) and
- R:5'-acaccatgagccccatccaggagta-3' (SEQ ID NO: 35)
- BMCC1 protein expression in cells in which DD3 expression or BMCC1 expression was suppressed was then confirmed by immunostaining and Western blotting using the anti-BMCC antibody (
FIGS. 9 and10 ). Procedures of the immunostaining are as follows. Cells which were left for 48 hours after introduction of siRNA were fixed with 10% formalin for 15 minutes at room temperature, and treated with PBS containing 0.1% TritonX for 10 minutes at room temperature. After that, the cells were treated with the anti-BMCC1 antibody (1/500 dilution) for 3 hours at room temperature, and then with an anti-rabbit antibody labeled with Alexa488 (product of Molecular Probes, Inc., 1/1000 dilution) for 2 hours at room temperature. The cells in which nuclei were stained with DAPI were observed under a confocal laser microscope (product of Leica Microsystems). An immunostaining image of BMCC1 protein in theLNCaP cells 48 hours after introduction of siRNA is shown inFIG. 9 (nuclei: blue, BMCC1: green, Cy3-siRNA: red). - Procedures of the Western blot are as follows. A total extraction solution of the cells which were left for 48 hours after introduction of siRNA was separated by a SDS-page and transferred to a PVDF membrane (product of Millipore Corporation), followed by treatment with the anti-BMCC1 antibody (1/500 dilution) for 3 hours at room temperature and with an anti-rabbit antibody labeled with HRP (product of Zymed Laboratories, Inc., 1/1500 dilution) for 2 hours at room temperature. The membrane was subjected to color development using ECL (product of GE Healthcare), and exposed to an X-ray film (product of Fujifilm Corporation) for detection. A Western blot image of BMCC1 protein in the LNCaP cells into which siRNA for DD3 was introduced is shown in
FIG. 10 . - Furthermore, using a WST-8 kit (product of Dojindo Molecular Technologies, Inc.), viability of the cells which were left for 48 hours after introduction of siRNA was measured following a manual thereof. Viability of the
cells 48 hours after introduction of siRNA is shown inFIG. 11 . - As a result, enhanced BMCC1 expression was confirmed in the LNCaP cells in which DD3 expression was suppressed by RT-PCR (
FIG. 8 ). In addition to an analysis at the mRNA level, BMCC1 expression was confirmed to be enhanced at the protein level as well by immunostaining and Western blotting using the anti-BMCC1 antibody (FIGS. 9 and10 ). Furthermore, it was confirmed that cell viability was suppressed in the LNCaP cells in which DD3 expression was suppressed (FIG. 11 ). - An effect of inhibition of DD3 expression on prostate cancer cells in the presence of cisplatin was examined by the below-described method. LNCaP cells into which siRNA for DD3 was introduced were treated with DMSO (product of Nacalai Tesque, Inc.) or cisplatin, CDDP (product of SIGMA Corporation) for 48 hours, and observed under a microscope (product of Leica Microsystems) (
FIG. 12 ). Also, viability of thecells 48 hours after siRNA introduction was measured using a WST-8 kit (FIG. 13 ). Apoptotic cells were detected by a TUNEL assay kit (product of F. Hoffman - La Roche, Ltd.) following a manual thereof, and quantified by observation under a confocal laser microscope (product of Leica Microsystems). The results of detection of apoptotic cells in theLNCaP cells 48 hours after siRNA introduction are shown inFIG. 14 (nuclei: blue, and apoptotic cells: red). Ratios of apoptotic cells/nuclei were determined for about 400 cells for each condition and were described as the ratio (%) at the bottom of each picture ofFIG. 14 . - As a result, it was elucidated that a sensitivity of the LNCaP cells in which DD3 expression was suppressed to an anti-cancer agent, cisplatin, was increased (
FIGS. 12 to 14 ). That is, effects of suppressing viability (FIGS. 12 and13 ) and promoting apoptosis (FIG. 14 ) of prostate cancer cells by cisplatin were enhanced additively and/or synergistically by suppressing DD3 expression. - It is known that androgen blockade therapy is effective for early-stage prostate cancer because most of the early-stage prostate cancer is androgen dependent. Also, viability of LNCaP cells is suppressed in the absence of androgen. In view of the foregoing, effects of suppression of DD3 expression and treatment with cisplatin on prostate cancer cells in the absence of androgen were examined following the below-described method. LNCaP cells were treated with DMSO or CDDP for 48, 72 hours in RPMI media containing 5% FBS containing androgen at a low concentration (product of Invitrogen Corporation), and viability of the cells was measured using a WST-8 kit (
FIG. 15 ). Then, LNCaP cells into which siRNA was introduced were treated with DMSO or CDDP (product of SIGMA Corporation) for 48 hours in RPMI media containing 5% FBS containing androgen at a low concentration, and viability of the cells was measured using a WST-8 kit (FIG. 16 ). - As a result, an effect of suppressing viability of the LNCaP cells in the absence of androgen was further enhanced by treatment with cisplatin (
FIG. 15 ). Prostate cancer treatment using hormone therapy in combination with an anti-cancer agent is clinically practiced. Interestingly, it was elucidated that by treating the LNCaP cells in which DD3 expression was suppressed with cisplatin in the absence of androgen, viability of the cells was suppressed synergistically (FIG. 16 ). Also, an effect of suppressing viability of the LNCaP cells in the absence of androgen was further enhanced by suppression of DD3 expression (FIG. 16 , data for non-addition of CDDP). Accordingly, from the results of Examples 7 and 8, viability of cells was found to be suppressed more effectively by employing treatment with cisplatin and/or removal of androgen concurrently in addition to suppression of DD3 expression. This result correlates with findings that BMCC1 expression was increased with either treatment with cisplatin or removal of androgen, in addition to suppression of DD3 expression. On the contrary, it was found that suppression of viability of cells was released, although partially, in the cells in which BMCC1 expression was suppressed in addition to suppression of DD3 expression (FIG. 11 ). Accordingly, suppression of DD3 expression and combination use thereof with another treatment method are considered effective as novel treatment methods for prostate cancer. - In view of the foregoing, a possibility that DD3 suppressed BMCC1 gene expression and promoted cancer progression was strongly suggested based on a finding that DD3 expression was enhanced in androgen-dependent cancer cells, which corresponded to early-stage prostate cancer, while BMCC1 gene expression was suppressively regulated as prostate cancer progressed (
FIG. 4 ) and a finding that BMCC1 gene expression was enhanced by suppression of DD3 expression (FIGS. 6 and7 ). Because BMCC1 has a function to promote apoptosis and acts as a cancer suppressor gene on one side, a method found by Examples of the present application, which directs to recovering BMCC1 expression by suppression of DD3 expression by siRNA, is considered effective for cancer treatment. In fact, based on that BMCC1 expression was enhanced at the mRNA level and the protein level by suppression of DD3 expression (FIGS. 6 to 10 ) and that cell viability of prostate cancer cells was suppressed and apoptosis was promoted by suppression of DD3 expression (FIGS. 11 and14 ), it was elucidated that suppression of DD3 expression enhanced BMCC1 gene expression and inhibited cancer progression. The above findings suggested that siRNA for DD3 was useful as a therapeutic agent for cancer. Also, based on the results from PC3 cells (FIG. 6 ), it is considered useful as a method for treatment of androgen independent prostate cancer, which is difficult to treat. - Furthermore, viability of cells was more effectively suppressed by employing treatment with cisplatin and/or removal of androgen concurrently in addition to suppression of DD3 expression (Examples 7 and 8). Accordingly, it was suggested that combination use of the therapeutic agent of the present invention with another treatment method such as an anti-cancer agent and androgen blockade therapy was effective.
-
- <110> Hisamitsu Pharmaceutical Co., Inc. Chiba Prefecture
- <120> CANCER MARKER AND THERAPEUTIC AGENT FOR CANCER
- <130> EP68163FZ
- <140> not yet assigned
<141> not yet assigned - <150>
JP2008-304897
<151> 2008-11-28 - <160> 35
- <170> PatentIn version 3.1
- <210> 1
<211> 31
<212> DNA
<213> Homo sapiens - <400> 1
ctgaacgatg aagggaaact gtcgataacgc 31 - <210> 2
<211> 24
<212> DNA
<213> Homo sapiens - <400> 2
cactgcctgc cacggcttct gttg 24 - <210> 3
<211> 28
<212> DNA
<213> Homo sapiens - <400> 3
cacagcagat gttgaactcc aggtgttc 28 - <210> 4
<211> 22
<212> DNA
<213> Homo sapiens - <400> 4
ggtgggaagg acctgatgatac 22 - <210> 5
<211> 23
<212> DNA
<213> Homo sapiens - <400> 5
gcacagggcg aggctcatcg atg 23 - <210> 6
<211> 20
<212> DNA
<213> Homo sapiens - <400> 6
accacagtcc atgccatcac 20 - <210> 7
<211> 20
<212> DNA
<213> Homo sapiens - <400> 7
tccaccaccc tgttgctgta 20 - <210> 8
<211> 20
<212> DNA
<213> Homo sapiens - <400> 8
gaagcctctg gtccagtcag 20 - <210> 9
<211> 20
<212> DNA
<213> Homo sapiens - <400> 9
cttcggccgt atattctgga 20 - <210> 10
<211> 19
<212> DNA
<213> Homo sapiens - <400> 10
tcctgcccat cctttaagg 19 - <210> 11
<211> 25
<212> RNA
<213> Homo sapiens - <400> 11
ggaaccaaga uacaaagaac ucuga 25 - <210> 12
<211> 27
<212> RNA
<213> Homo sapiens - <400> 12
ucagaguucu uuguaucuug guuccuu 27 - <210> 13
<211> 25
<212> DNA
<213> Homo sapiens - <400> 13
ucacuagaaa cagcaagaug acaat 25 - <210> 14
<211> 27
<212> RNA
<213> Homo sapiens - <400> 14
auugucaucu ugcuguuucu agugaug 27 - <210> 15
<211> 25
<212> DNA
<213> Homo sapiens - <400> 15
ggcauacuau aucaacuuug auuct 25 - <210> 16
<211> 27
<212> RNA
<213> Homo sapiens - <400> 16
agaaucaaag uugauauagu augccaa 27 - <210> 17
<211> 25
<212> RNA
<213> Homo sapiens - <400> 17
cuuccucucu uucucucccu uguga 25 - <210> 18
<211> 27
<212> RNA
<213> Homo sapiens - <400> 18
ucacaaggga gagaaagaga ggaagga 27 - <210> 19
<211> 22
<212> DNA
<213> Homo sapiens - <400> 19
ccagttcagt gctcagggtt ta 22 - <210> 20
<211> 21
<212> DNA
<213> Homo sapiens - <400> 20
gcattcccac ccttacctca a 21 - <210> 21
<211> 22
<212> DNA
<213> Homo sapiens - <400> 21
cacagagatc cctgggagaa at 22 - <210> 22
<211> 22
<212> DNA
<213> Homo sapiens - <400> 22
ctgcccatcc tttaaggaacac 22 - <210> 23
<211> 20
<212> PRT
<213> Homo sapiens - <400> 23
- <210> 24
<211> 25
<212> DNA
<213> Homo sapiens - <400> 24
ggagaaggau auugacuuga agctg 25 - <210> 25
<211> 28
<212> RNA
<213> Homo sapiens - <400> 25
cagcuucaag ucaauauccu uucuccau 28 - <210> 26
<211> 25
<212> DNA
<213> Homo sapiens - <400> 26
ggaguaucag gaagcaaauc aggta 25 - <210> 27
<211> 27
<212> RNA
<213> Homo sapiens - <400> 27
uaccugauuu gcuuccugau acuccaa 27 - <210> 28
<211> 25
<212> RNA
<213> Homo sapiens - <400> 28
cccagugaga uaaacaauga agcag 25 - <210> 29
<211> 27
<212> RNA
<213> Homo sapiens - <400> 29
cugcuucauu guuuaucuca cugggug 27 - <210> 30
<211> 27
<212> RNA
<213> Homo sapiens - <400> 30
ggaguuagau uuaugcauau ugugguu 27 - <210> 31
<211> 25
<212> RNA
<213> Homo sapiens - <400> 31
ccacaauaug cauaaaucua acucc 25 - <210> 32
<211> 20
<212> DNA
<213> Homo sapiens - <400> 32
gcctctcgtg gcagggcagt 20 - <210> 33
<211> 20
<212> DNA
<213> Homo sapiens - <400> 33
gggtgaactt gcgcacacac 20 - <210> 34
<211> 25
<212> DNA
<213> Homo sapiens - <400> 34
tcaaaagagc cgctgaaggg aaaca 25 - <210> 35
<211> 25
<212> DNA
<213> Homo sapiens - <400> 35
acaccatgag ccccatccag gagta 25
Claims (10)
- A method for detecting cancer comprising measuring the level of BMCC1 gene expression in a specimen and using the level of BMCC1 gene expression as an indication, wherein the cancer is selected from the group consisting of bladder cancer and uterine cancer.
- The method according to Claim 1, which comprises
a step of measuring a level of BMCC1 gene expression in a specimen with a suspicion of cancer;
a step of comparing the level of BMCC1 gene expression with levels of BMCC1 gene expression in a normal specimen and in a cancer specimen; and
a step of judging the specimen with a suspicion of cancer as cancer in a case where the level of BMCC1 gene expression in the specimen with a suspicion of cancer is (i) lower than the level of BMCC1 gene expression in the normal specimen, (ii) the same level as the level of BMCC1 gene expression in the cancer specimen, or, falls into both (i) and (ii). - The method according to Claim 2, wherein the specimen is a cell or a piece of tissue.
- A siRNA targeting DD3, wherein the siRNA is double-stranded siRNA comprising a pair of oligonucleotides of any one of (a) to (c) as described below;(a) an oligonucleotide comprising a sequence described in SEQ ID NO: 11 and an oligonucleotide comprising a sequence described in SEQ ID NO: 12;(b) an oligonucleotide comprising a sequence described in SEQ ID NO: 13 and an oligonucleotide comprising a sequence described in SEQ ID NO: 14; and(c) an oligonucleotide comprising a sequence described in SEQ ID NO: 15 and an oligonucleotide comprising a sequence described in SEQ ID NO: 16.
- A therapeutic agent for cancer which comprises the siRNA according to Claim 4 as an active ingredient.
- The therapeutic agent for cancer according to Claim 5, wherein the cancer is selected from the group consisting of prostate cancer, lung cancer, gastric cancer, bladder cancer, and uterine cancer.
- The therapeutic agent for cancer according to Claim 5, wherein the cancer is prostate cancer.
- The therapeutic agent for cancer according to Claim 7, which further comprises an anti-cancer agent.
- The therapeutic agent for cancer according to Claim 8, wherein the anti-cancer agent is cisplatin.
- The therapeutic agent for cancer according to any one of Claims 7 to 9, which further comprises an anti-androgen agent.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008304897 | 2008-11-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2204177A1 EP2204177A1 (en) | 2010-07-07 |
EP2204177B1 true EP2204177B1 (en) | 2015-08-12 |
Family
ID=42046225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09177321.8A Not-in-force EP2204177B1 (en) | 2008-11-28 | 2009-11-27 | Cancer marker and therapeutic agent for cancer |
Country Status (3)
Country | Link |
---|---|
US (1) | US8202690B2 (en) |
EP (1) | EP2204177B1 (en) |
JP (1) | JP2010148501A (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9175291B2 (en) | 2012-10-11 | 2015-11-03 | Isis Pharmaceuticals Inc. | Modulation of androgen receptor expression |
WO2016019311A1 (en) * | 2014-08-01 | 2016-02-04 | Stc.Unm | Methods for the detection and treatment of prostate cancer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2324503T3 (en) | 1997-04-10 | 2009-08-07 | Stichting Katholieke Universiteit University Medical Centre Nijmegen | PCA3, PCA3 GENES AND METHODS OF USE. |
US6897024B2 (en) | 2001-05-31 | 2005-05-24 | Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen | Nucleic acid molecules comprising the promoter for PCA3, and uses thereof |
JP4723133B2 (en) | 2001-08-24 | 2011-07-13 | 千葉県 | Novel human BMCC1 gene |
US20050272052A1 (en) * | 2002-04-09 | 2005-12-08 | Affymetrix, Inc. | Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer |
US7659062B2 (en) * | 2003-06-03 | 2010-02-09 | The Board of Trustee of the University of Arkansas System | Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors |
-
2009
- 2009-11-25 US US12/626,346 patent/US8202690B2/en not_active Expired - Fee Related
- 2009-11-25 JP JP2009267463A patent/JP2010148501A/en active Pending
- 2009-11-27 EP EP09177321.8A patent/EP2204177B1/en not_active Not-in-force
Also Published As
Publication number | Publication date |
---|---|
EP2204177A1 (en) | 2010-07-07 |
US20100136139A1 (en) | 2010-06-03 |
JP2010148501A (en) | 2010-07-08 |
US8202690B2 (en) | 2012-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6781184B2 (en) | Methods for Prognosis and Treatment of Cancer Metastasis | |
JP7050702B2 (en) | Methods for diagnosing and treating cancer based on the expression status and mutation status of NRF2 and its downstream target gene | |
EP3693476B1 (en) | Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status | |
Yang et al. | DNMT3B overexpression by deregulation of FOXO3a-mediated transcription repression and MDM2 overexpression in lung cancer | |
MX2014014802A (en) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis. | |
Xiao et al. | miR-29c contribute to glioma cells temozolomide sensitivity by targeting O6-methylguanine-DNA methyltransferases indirectly | |
WO2020041243A1 (en) | Methods related to bronchial premalignant lesion severity and progression | |
US20210393597A1 (en) | Targeting the transcription factor nf-kb with harmine | |
JP2023504786A (en) | Use of a composition containing an ERRγ inhibitor as an active ingredient for enhancing anticancer effects | |
Lin et al. | Long non-coding RNA MIR503HG serves as a tumor suppressor in non-small cell lung cancer mediated by wnt1. | |
US10697020B2 (en) | MicroRNA-129 as a biomarker for colorectal cancer | |
EP2204177B1 (en) | Cancer marker and therapeutic agent for cancer | |
EP2998742A1 (en) | Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased | |
US20210145811A1 (en) | Treatment of cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype | |
JP2019501959A (en) | Use of Akt2 in tumor diagnosis and treatment | |
WO2011014872A2 (en) | Compositions and methods for diagnosing, treating or preventing neoplasias | |
JP2018529362A (en) | Prevention, diagnosis and treatment of cancers that overexpress GPR160 | |
US20210393651A1 (en) | Targeting the oncogenic transcription factor stat5 with mineralocorticoid analogues | |
WO2015153871A2 (en) | EXPRESSION LEVELS OF BCL-xL, BCL2, BCL-w, AND BAD AND CANCER THERAPIES | |
EP4352516A1 (en) | Use of casd1 as a biomarker of a cancer expressing the o-acetylated-gd2 ganglioside | |
US8420618B2 (en) | MicroRNA-based method for anti-colorectal cancer effects and prognosis of colorectal cancer | |
Franklin | Exploring the Metabolic Regulation of p53 from Ribosomal Proteins to Very Long Chain Fatty Acids | |
WO2022229846A1 (en) | Treatment of cancer using a transforming growth factor beta receptor type 1 inhibitor | |
EP2718462B1 (en) | Method for predicting the response to treatment with an her2-blocking agent | |
TW201100798A (en) | Method for prediction of therapeutic effect of chemotherapy employing expression level of dihydropyrimidine dehydrogenase gene as measure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
17P | Request for examination filed |
Effective date: 20110105 |
|
17Q | First examination report despatched |
Effective date: 20140312 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20150409 |
|
INTG | Intention to grant announced |
Effective date: 20150422 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 741507 Country of ref document: AT Kind code of ref document: T Effective date: 20150815 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602009032779 Country of ref document: DE Representative=s name: GRUENECKER PATENT- UND RECHTSANWAELTE PARTG MB, DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602009032779 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 7 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 741507 Country of ref document: AT Kind code of ref document: T Effective date: 20150812 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20150812 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151112 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151113 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151212 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151214 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602009032779 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 Ref country code: LU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151127 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
26N | No opposition filed |
Effective date: 20160513 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20151130 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20151130 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20151127 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20091127 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20171121 Year of fee payment: 9 Ref country code: FR Payment date: 20171012 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20171122 Year of fee payment: 9 Ref country code: IT Payment date: 20171123 Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602009032779 Country of ref document: DE |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20181127 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181130 Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181127 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190601 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181127 |